US Patent 11278552 Combinations including ABX196 for the treatment of cancer
Patent 11278552 was granted and assigned to Abivax on March, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Didier Scherrer0
Hartmut Ehrlich0
Philippe Pouletty0
Sandrine Crabe0
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 23 Mar, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
Article (+196 characters)
US Patent 11278552 Combinations including ABX196 for the treatment of cancer
Article
An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11278552
Date of patent
March 22, 2022
Patent application number
16333531
Date Filed
September 14, 2017
Patent primary examiner
Find more entities like US Patent 11278552 Combinations including ABX196 for the treatment of cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.